Have a feature idea you'd love to see implemented?
Let us know!
ZVRA Zevra Therapeutics Inc
Price (delayed)
$9.13
Market cap
$487.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.97
Enterprise value
$493.21M
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes
Highlights
Zevra Therapeutics's equity has soared by 115% from the previous quarter and by 3.4% YoY
ZVRA's revenue is up by 50% YoY and by 3.3% QoQ
The quick ratio has dropped by 55% year-on-year but it has increased by 48% since the previous quarter
ZVRA's gross profit is down by 8% from the previous quarter but it is up by 7% YoY
Zevra Therapeutics's net income has decreased by 37% QoQ
ZVRA's debt is up by 34% year-on-year
Key stats
What are the main financial stats of ZVRA
Market
Valuations
Earnings
Shares outstanding
53.38M
Market cap
$487.32M
Enterprise value
$493.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.89
Price to sales (P/S)
17.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.9
Revenue
$24.79M
EBIT
-$79.01M
EBITDA
-$73.48M
Free cash flow
-$69.65M
Per share
Balance sheet
Liquidity
EPS
-$1.97
Free cash flow per share
-$1.46
Book value per share
$1.33
Revenue per share
$0.52
TBVPS
$2.43
Total assets
$191.55M
Total liabilities
$121.78M
Debt
$59.93M
Equity
$69.77M
Working capital
$64.96M
Debt to equity
0.86
Current ratio
2.88
Quick ratio
2.82
Net debt/EBITDA
-0.08
Margins
Efficiency
Dividend
EBITDA margin
-296.5%
Gross margin
67.5%
Net margin
-342.6%
Operating margin
-348%
Return on assets
-51.5%
Return on equity
-159.5%
Return on invested capital
-139.4%
Return on capital employed
-50.3%
Return on sales
-318.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZVRA stock price
How has the Zevra Therapeutics stock price performed over time
Intraday
1.78%
1 week
1.11%
1 month
6.91%
1 year
102.44%
YTD
39.39%
QTD
31.56%
Financial performance
How have Zevra Therapeutics's revenue and profit performed over time
Revenue
$24.79M
Gross profit
$16.74M
Operating income
-$86.26M
Net income
-$84.93M
Gross margin
67.5%
Net margin
-342.6%
ZVRA's net margin has dropped by 178% year-on-year and by 32% since the previous quarter
The operating income has plunged by 97% YoY and by 16% from the previous quarter
ZVRA's revenue is up by 50% YoY and by 3.3% QoQ
Zevra Therapeutics's net income has decreased by 37% QoQ
Growth
What is Zevra Therapeutics's growth rate over time
Valuation
What is Zevra Therapeutics stock price valuation
P/E
N/A
P/B
6.89
P/S
17.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.9
Zevra Therapeutics's EPS has decreased by 25% QoQ
Zevra Therapeutics's equity has soared by 115% from the previous quarter and by 3.4% YoY
The price to book (P/B) is 41% higher than the last 4 quarters average of 4.9
ZVRA's P/S is 85% above its 5-year quarterly average of 9.5 and 80% above its last 4 quarters average of 9.8
ZVRA's revenue is up by 50% YoY and by 3.3% QoQ
Efficiency
How efficient is Zevra Therapeutics business performance
The company's return on assets has shrunk by 194% YoY and by 26% QoQ
Zevra Therapeutics's return on sales has shrunk by 181% YoY and by 32% QoQ
Zevra Therapeutics's return on invested capital has shrunk by 55% QoQ
ZVRA's ROE is down by 35% QoQ
Dividends
What is ZVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZVRA.
Financial health
How did Zevra Therapeutics financials performed over time
The total assets is 57% greater than the total liabilities
The total liabilities has soared by 70% YoY and by 9% from the previous quarter
The quick ratio has dropped by 55% year-on-year but it has increased by 48% since the previous quarter
ZVRA's debt is 14% smaller than its equity
Zevra Therapeutics's equity has soared by 115% from the previous quarter and by 3.4% YoY
The debt to equity has plunged by 53% from the previous quarter but it has grown by 30% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.